Astrazeneca AZN
NYSE AZN
$184.24 -1.24 (-0.67%)
As of: Nov 12, 2026 · 2:33 PM EST

Astrazeneca (AZN) Income from Continuing Operations (2009 - 2026)

Updated

Astrazeneca's Income from Continuing Operations came in at $4.8 billion for Q3 2026, up 21.4% from $3.95 billion a year earlier and up 91.4% from the prior quarter.

Analysis

Astrazeneca (AZN) Income from Continuing Operations (2009 - 2026) Analysis & Trends

Over the trailing twelve months to Sep 30, 2026, Astrazeneca reported Income from Continuing Operations of $14.98 billion, up 23.7% year-over-year; for FY2025, it was $10.23 billion, up 45.3% from FY2024.

  • Income from Continuing Operations carries a five-year compound annual growth rate of 26.6% (FY2020 to FY2025).
  • Going back by year, Income from Continuing Operations was $7.04 billion in FY2024 (-10.9%), $7.9 billion in FY2023 (+139.9%), $3.29 billion in FY2022 and $115 million in FY2021 (-96.3%).
  • The Q3 2026 figure represents the highest quarterly Income from Continuing Operations since Q4 2014.
  • Year-over-year, Income from Continuing Operations has increased for 15 consecutive quarters, with growth averaging 43.0% over the last eight quarters.
  • The fastest year-over-year change in Income from Continuing Operations over five years came in Q3 2023 (growth of 853.5%), and the weakest in Q1 2022 (a decline of 56.6%).
  • Business Quant data shows AZN's Income from Continuing Operations at $2.51 billion (Q2 2026), $4.75 billion (Q1 2026) and $2.93 billion (Q4 2025) in the three quarters before Q3 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 6.45 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 210.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 4.22 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 5.07 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 4.80 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 3.86 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 2.43 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 3.25 Bn
10 Vertex Pharmaceuticals 138.90 Bn 106.64 Bn 2.91 Bn 653.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 4.80 Bn
Jun 30, 2026 2.51 Bn
Mar 31, 2026 4.75 Bn
Dec 31, 2025 2.93 Bn
Sep 30, 2025 3.95 Bn
Jun 30, 2025 2.45 Bn
Mar 31, 2025 3.88 Bn
Dec 31, 2024 1.83 Bn
Sep 30, 2024 2.22 Bn
Jun 30, 2024 1.93 Bn
Mar 31, 2024 3.42 Bn
Dec 31, 2023 835.00 Mn
Sep 30, 2023 1.93 Bn
Jun 30, 2023 1.82 Bn
Mar 31, 2023 2.72 Bn
Dec 31, 2022 654.00 Mn
Sep 30, 2022 202.00 Mn
Jun 30, 2022 360.00 Mn
Mar 31, 2022 718.00 Mn
Dec 31, 2021 -926.00 Mn
API Access

Astrazeneca Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=AZN&period=max&api_key=YOUR_API_KEY